Geneva, Aug 12 (IANS/EFE) The toll from the Ebola virus disease in West Africa has risen to 1,013, leading the World Health Organisation (WHO) Tuesday to approve the use of experimental drugs to fight the disease.
The UN health institution indicated that 52 more patients had died since last Friday, while there were 69 new cases over the same period, bringing the number of affected to 1,848.
In a statement, the WHO's Ethics Committee said that in the light of the scale of the outbreak and the high number of deaths, it was ethical to use untested drugs against the Ebola virus.
The announcement came as Liberia, one of the worst-affected countries with 323 deaths and 599 cases, prepared to receive experimental treatment from the US in the coming days.
Washington Tuesday agreed to provide Liberia with experimental serum ZMapp, which has been used with success on two US aid workers infected with Ebola in Liberia and repatriated to the US.
The move came after Liberia's President, Ellen Johnson Sirleaf, asked the US for the drug to fight the virus.
The White House and the US Food and Drug Administration (FDA) approved the request for the serum to treat Liberian doctors currently infected with the Ebola virus.
A US government representative is expected to bring the drug into the country later this week.
Liberia registered the highest number of new infections and deaths between Aug 7 and 9, when 29 patients lost their lives and 45 new infections were recorded, the WHO reported Tuesday.
Sierra Leone followed with 17 deaths and 13 new patients, while six people died and 11 new cases were recorded in Guinea Conakry over that period.
Overall, Guinea is the country with the highest mortality, with 373 deaths, followed by Liberia with 323.
In Sierra Leone, the toll has risen to 315 out of 730 cases, and in Nigeria only 13 cases have been diagnosed, of which two were fatal.
--IANS/EFE
ab/dg
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
